Colon Cancer Risk can be Evaluated With the Blood Test That Checks for Inflammation

Scientists have found that the blood test used to assess the level of inflammation in the body may be of use in evaluating colon cancer risk.

Vanderbilt-Ingram Cancer Center's Gong Yang and colleagues show that levels of C-reactive protein (CRP), a protein produced by the liver in response to inflammation, are increased in women with colon cancer.

Research: Gene Test Shows Who Could Benefit from Statins to Reduce Colon Cancer Risk
Study says genetic test can help determine in which patients cholesterol-lowering statin drugs might have the most benefit in also reducing the risk of colorectal cancer

Blood tests for CRP are typically used as a non-specific marker for infection and inflammatory conditions. A more sensitive CRP test (hs-CRP) can help determine heart disease risk.

Previous studies suggested an association between elevated CRP levels and colon cancer, which fits with the hypothesis that chronic inflammation increases cancer risk. But due to small population sizes and mixed results of the studies, the relationship between CRP and colon cancer risk remains controversial.

"Although cancer-induced inflammation has been proposed to explain the relationship between elevated CRP levels and cancer risk, this hypothesis has not been well evaluated in previous studies," said Yang.

Bowel Inflammation and Colon Cancer can be Delayed With an Experimental Vaccine
A novel experimental vaccine may help slow the development of bowel inflammation and colon cancer, according to researchers at the University of Pittsburgh School of Medicine.

"This study, the largest study thus far on circulating CRP and colorectal cancer risk, allows us to test this hypothesis in a more definitive manner," Yang added.

The researchers measured CRP levels in blood samples from women participating in the Shanghai Women's Health Study, a large population-based prospective study of nearly 75,000 Chinese women.

Evaluating Costs and Benefits of Recent Colon Cancer Therapies
Novel chemotherapy agents seem to hold promise with better survival time for patients with metastastic colorectal cancer, though it will be very expensive.

In an analysis of 209 cases of colon cancer and 279 healthy controls, the researchers found that women with CRP levels in the highest quartile (the upper 25 percent) had a 2.5-times greater risk of colon cancer compared with women in the lowest quartile.

To examine if there is a causal relationship between blood CRP levels and colorectal cancer risk, they stratified the samples by the time intervals between blood sample collection and disease diagnosis.

Irritable Bowel Syndrome Patients at No Colon Cancer Risk
According to a new research, irritable bowel syndrome patients are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than fit individuals undergoing colonoscopies.

They found that the increased risk was primarily seen in women with high blood CRP levels measured within the three years prior to diagnosis. As the interval between the blood draw and cancer diagnosis increased, the association between CRP levels and risk faded.

Because the increased risk associated was greatest in the first years after CRP measurement, Yang believes that high CRP levels may arise largely from the patient's inflammatory response to cancer.

Therefore, high CRP may be more of a "risk marker" rather than a "risk factor".

The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR).

Source-ANI
SAV